Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.

This trial was conducted to evaluate the safety and immunogenicity of two virosome formulated malaria peptidomimetics derived from Plasmodium falciparum AMA-1 and CSP in malaria semi-immune adults and children.The design was a prospective randomized, double-blind, controlled, age-deescalating study...

Full description

Bibliographic Details
Main Authors: Patrick Georges Cech, Thomas Aebi, Mwanajaa Shomari Abdallah, Maxmillian Mpina, Ester Barnabas Machunda, Nicole Westerfeld, Sabine Alexandra Stoffel, Rinaldo Zurbriggen, Gerd Pluschke, Marcel Tanner, Claudia Daubenberger, Blaise Genton, Salim Abdulla
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3142124?pdf=render

Internet

http://europepmc.org/articles/PMC3142124?pdf=render

Similar Items